Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 6/20 | 0.73 |
| ▸ | NOS1 | P29475 | 7/20 | 0.70 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | DHFR | P00374 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20572287 | 0.84 | PIK3CG (0.73) | PIK3CGNOS1PIK3CAPIK3CBHDAC6 | |
| SCHEMBL3533505 | 0.84 | PIK3CG (1.00) | PIK3CGNOS1PIK3CAPIK3CBHDAC6 | |
| SCHEMBL8813951 | 0.84 | PIK3CG (0.72) | PIK3CGNOS1PIK3CAPIK3CBHDAC6 | |
| SCHEMBL4454197 | 0.84 | NOS1 (0.72) | PIK3CGNOS1PIK3CAPIK3CBHDAC6 | |
| SCHEMBL5516535 | 0.82 | NOS1 (1.00) | PIK3CGNOS1PIK3CAPIK3CBHDAC6 | |
| SCHEMBL3755577 | 0.80 | NOS1 (0.61) | PIK3CGNOS1PIK3CAPIK3CBHDAC6 | |
| SCHEMBL8813941 | 0.76 | PIK3CG (0.54) | PIK3CGNOS1PIK3CAPIK3CBHDAC6 | |
| SCHEMBL12997453 | 0.76 | NOS1 (0.56) | PIK3CGNOS1PIK3CAPIK3CBHDAC6 | |
| SCHEMBL11453447 | 0.75 | ADK (0.72) | PIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL8897194 | 0.75 | PIK3CG (0.60) | PIK3CGNOS1PIK3CAPIK3CBHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC. | 2010-11-04 | — | — | US | disclosed |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2007-09-06 | — | — | US | disclosed |
| EP-1144412-A1 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | K.U. Leuven Research & Development (BE) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000039129-A1 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2000-07-06 | — | — | WO | disclosed |
| WO-1997021711-A1 | PROCESS FOR PREPARING 4-AMINOPTERIDINE DERIVATIVES | LONZA AG (CH) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | RBP1, RBP4, VCAM1 | PIK3CG 2378/4885NOS1 1249/4885PIK3CA 3097/4885 |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | RBP1, RBP4, VCAM1 | PIK3CG 2378/4885NOS1 1249/4885PIK3CA 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.